IGHV1-3 E3 Protein: Potential Drug Targets (G28473)

Target Name: IGHV1-3

NCBI ID: G28473

IGHV1-3

Other Name(s): VI-3B | immunoglobulin heavy variable 1-3 | Immunoglobulin heavy variable 1-3 | IGHV13

IGHV1-3 E3 Protein: Potential Drug Targets

IGHV1-3 (interleukin-gamma virus 1A subtype 3) is a type of virus that is known to cause a variety of respiratory and cardiac problems in humans. The virus is a member of the family Poxviridae, and its official name is IGHV1-3.

The IGHV1-3 virus is a double-stranded DNA virus that has a length of approximately 190 base pairs. It has a unique structure, with a genome that is composed of 11 open reading frames (ORFs). The ORFs are arranged in a specific order, and they encode the different proteins that are present in the virus.

One of the most important proteins that is encoded by the IGHV1-3 virus is the IGHV1-3 E3 protein. This protein is a type of transmembrane protein that is involved in the virus's replication process. The IGHV1-3 E3 protein has been shown to play a crucial role in the virus's replication and has been identified as a potential drug target.

The IGHV1-3 E3 protein is made up of 1,212 amino acids and has a molecular weight of 185.5 kDa. It is located at the outer membrane of the IGHV1-3 virus and is involved in the formation of the virus's replication complex. The IGHV1-3 E3 protein has been shown to interact with a variety of different proteins, including the IGHV1-3 F protein.

The IGHV1-3 F protein is another type of transmembrane protein that is encoded by the IGHV1-3 virus. It is a type of cytoplasmic protein and is involved in the virus's replication process. The IGHV1-3 F protein has been shown to interact with the IGHV1-3 E3 protein, and it is possible that the two proteins work together to facilitate the virus's replication.

In addition to its role in the virus's replication, the IGHV1-3 E3 protein has also been shown to play a potential role in the immune response. The IGHV1-3 virus has been shown to induce an immune response in humans, and the IGHV1-3 E3 protein has been shown to be involved in this process.

The IGHV1-3 E3 protein has also been shown to be expressed in a variety of different cell types, including human epithelial cells, macrophages, and dendritic cells. This suggests that the IGHV1-3 E3 protein may be involved in a variety of different cellular processes, and it may be a potential drug target for a variety of different diseases.

Despite its potential role in the immune response and virus replication, the IGHV1-3 E3 protein is not yet a drug target. Further research is needed to understand the full extent of its function and to identify potential drug targets.

In conclusion, IGHV1-3 (VI-3B) is a double-stranded DNA virus that is known to cause a variety of respiratory and cardiac problems in humans. The IGHV1-3 E3 protein is a transmembrane protein that is involved in the virus's replication process and has been shown to play a crucial role in the immune response. Further research is needed to understand its full extent of function and to identify potential drug targets.

Protein Name: Immunoglobulin Heavy Variable 1-3

Functions: V region of the variable domain of immunoglobulin heavy chains that participates in the antigen recognition (PubMed:24600447). Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:22158414, PubMed:20176268). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:20176268, PubMed:17576170)

The "IGHV1-3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGHV1-3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets